Evvy is a precision women's health company that uses the vaginal microbiome to discover and apply overlooked female biomarkers, with the stated aim of closing the gender health gap and improving outcomes across a woman's lifespan. Its work spans metagenomics, microbiome sequencing, bioinformatics and machine learning, applied to clinical test validation and biomarker discovery.
The company's flagship product is the Vaginal Microbiome Test, described as the first and only peer-reviewed, metagenomics-based test of its kind. It analyses more than 700 bacteria and fungi with industry-leading sensitivity; validation of the test was published in the peer-reviewed journal Diagnostics. The test is used across vaginal symptoms, UTIs, fertility and menopause. It is paired with an AI-powered personalised care platform that delivers precision care to patients and providers, and that serves over 100,000 patients and 3,000 providers nationwide.
Underlying these products is what Evvy describes as the world's largest dataset on the vaginal microbiome, a proprietary resource intended to support research into infertility, preterm birth, gynecological cancers and related conditions. Findings from the company's work have been presented at clinical conferences including ACOG, ASRM, IDSOG, ISSVD and ISSWSH.
Evvy operates across the United States, with named investors including General Catalyst, Left Lane Capital, US Fertility and Labcorp. Its activity touches women's health, diagnostics, fertility and reproductive health, menopause care, urology and UTI care, gynecology and gynecological oncology, maternal health and digital precision medicine.
